Cargando…

Levels of acylation stimulating protein and the complement component 3 precursor are associated with the occurrence and development of coronary heart disease

The aim of the present study was to investigate whether acylation stimulating protein (ASP) and complement component 3 (C3) are associated with the occurrence and development of coronary heart disease (CHD). The participants of the study were divided into three groups, including the healthy control...

Descripción completa

Detalles Bibliográficos
Autores principales: JIANG, HONGLEI, GUO, MIAO, DONG, LINPING, CAO, CHUNLIN, WANG, DONG, LIANG, XIAOTANG, GUO, FANG, XING, ZHAOQIN, BU, PEILI, LIU, JIDONG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4217778/
https://www.ncbi.nlm.nih.gov/pubmed/25371745
http://dx.doi.org/10.3892/etm.2014.2018
_version_ 1782342446107066368
author JIANG, HONGLEI
GUO, MIAO
DONG, LINPING
CAO, CHUNLIN
WANG, DONG
LIANG, XIAOTANG
GUO, FANG
XING, ZHAOQIN
BU, PEILI
LIU, JIDONG
author_facet JIANG, HONGLEI
GUO, MIAO
DONG, LINPING
CAO, CHUNLIN
WANG, DONG
LIANG, XIAOTANG
GUO, FANG
XING, ZHAOQIN
BU, PEILI
LIU, JIDONG
author_sort JIANG, HONGLEI
collection PubMed
description The aim of the present study was to investigate whether acylation stimulating protein (ASP) and complement component 3 (C3) are associated with the occurrence and development of coronary heart disease (CHD). The participants of the study were divided into three groups, including the healthy control (n=42), metabolic syndrome (MS, n=56) and CHD (n=62) groups. An enzyme-linked immunosorbent assay was used to measure the ASP concentrations, while an immunoturbidimetric assay was employed to determine the C3 concentrations. In addition, coronary angiography was performed to determine the severity of coronary artery disease in the CHD group. The CHD group was divided into three subgroups, according to the final Gensini score of coronary artery stenosis for each patient (mild, ≤20 points; moderate, 21–40 points; severe, >40 points). Western blotting and quantitative reverse transcription-polymerase chain reaction (RT-PCR) were performed to analyze the protein and mRNA expression levels of C3 in the CHD subgroups and the healthy control group. The concentrations of ASP and C3 in the CHD group were found to be significantly higher compared with the control and MS groups. In addition, the levels of ASP and C3 in the mild and moderate CHD subgroups were significantly higher compared with the healthy controls or mild CHD patients. Furthermore, the protein expression levels of C3 in the moderate and severe CHD patients were found to be significantly higher compared with the healthy individuals and the mild CHD patients. The quantitative RT-PCR results revealed that the mRNA expression levels of C3 in the moderate and severe CHD patients were significantly higher compared with the healthy control group and the mild CHD patients. Furthermore, the mean levels of C3 transcripts in the severe CHD patients were found to be higher compared with the moderate CHD subgroup (P<0.05). Therefore, ASP and C3 were found to be associated with the occurrence and development of CHD; thus, may be used as novel indexes for CHD.
format Online
Article
Text
id pubmed-4217778
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-42177782014-11-04 Levels of acylation stimulating protein and the complement component 3 precursor are associated with the occurrence and development of coronary heart disease JIANG, HONGLEI GUO, MIAO DONG, LINPING CAO, CHUNLIN WANG, DONG LIANG, XIAOTANG GUO, FANG XING, ZHAOQIN BU, PEILI LIU, JIDONG Exp Ther Med Articles The aim of the present study was to investigate whether acylation stimulating protein (ASP) and complement component 3 (C3) are associated with the occurrence and development of coronary heart disease (CHD). The participants of the study were divided into three groups, including the healthy control (n=42), metabolic syndrome (MS, n=56) and CHD (n=62) groups. An enzyme-linked immunosorbent assay was used to measure the ASP concentrations, while an immunoturbidimetric assay was employed to determine the C3 concentrations. In addition, coronary angiography was performed to determine the severity of coronary artery disease in the CHD group. The CHD group was divided into three subgroups, according to the final Gensini score of coronary artery stenosis for each patient (mild, ≤20 points; moderate, 21–40 points; severe, >40 points). Western blotting and quantitative reverse transcription-polymerase chain reaction (RT-PCR) were performed to analyze the protein and mRNA expression levels of C3 in the CHD subgroups and the healthy control group. The concentrations of ASP and C3 in the CHD group were found to be significantly higher compared with the control and MS groups. In addition, the levels of ASP and C3 in the mild and moderate CHD subgroups were significantly higher compared with the healthy controls or mild CHD patients. Furthermore, the protein expression levels of C3 in the moderate and severe CHD patients were found to be significantly higher compared with the healthy individuals and the mild CHD patients. The quantitative RT-PCR results revealed that the mRNA expression levels of C3 in the moderate and severe CHD patients were significantly higher compared with the healthy control group and the mild CHD patients. Furthermore, the mean levels of C3 transcripts in the severe CHD patients were found to be higher compared with the moderate CHD subgroup (P<0.05). Therefore, ASP and C3 were found to be associated with the occurrence and development of CHD; thus, may be used as novel indexes for CHD. D.A. Spandidos 2014-12 2014-10-13 /pmc/articles/PMC4217778/ /pubmed/25371745 http://dx.doi.org/10.3892/etm.2014.2018 Text en Copyright © 2014, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
JIANG, HONGLEI
GUO, MIAO
DONG, LINPING
CAO, CHUNLIN
WANG, DONG
LIANG, XIAOTANG
GUO, FANG
XING, ZHAOQIN
BU, PEILI
LIU, JIDONG
Levels of acylation stimulating protein and the complement component 3 precursor are associated with the occurrence and development of coronary heart disease
title Levels of acylation stimulating protein and the complement component 3 precursor are associated with the occurrence and development of coronary heart disease
title_full Levels of acylation stimulating protein and the complement component 3 precursor are associated with the occurrence and development of coronary heart disease
title_fullStr Levels of acylation stimulating protein and the complement component 3 precursor are associated with the occurrence and development of coronary heart disease
title_full_unstemmed Levels of acylation stimulating protein and the complement component 3 precursor are associated with the occurrence and development of coronary heart disease
title_short Levels of acylation stimulating protein and the complement component 3 precursor are associated with the occurrence and development of coronary heart disease
title_sort levels of acylation stimulating protein and the complement component 3 precursor are associated with the occurrence and development of coronary heart disease
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4217778/
https://www.ncbi.nlm.nih.gov/pubmed/25371745
http://dx.doi.org/10.3892/etm.2014.2018
work_keys_str_mv AT jianghonglei levelsofacylationstimulatingproteinandthecomplementcomponent3precursorareassociatedwiththeoccurrenceanddevelopmentofcoronaryheartdisease
AT guomiao levelsofacylationstimulatingproteinandthecomplementcomponent3precursorareassociatedwiththeoccurrenceanddevelopmentofcoronaryheartdisease
AT donglinping levelsofacylationstimulatingproteinandthecomplementcomponent3precursorareassociatedwiththeoccurrenceanddevelopmentofcoronaryheartdisease
AT caochunlin levelsofacylationstimulatingproteinandthecomplementcomponent3precursorareassociatedwiththeoccurrenceanddevelopmentofcoronaryheartdisease
AT wangdong levelsofacylationstimulatingproteinandthecomplementcomponent3precursorareassociatedwiththeoccurrenceanddevelopmentofcoronaryheartdisease
AT liangxiaotang levelsofacylationstimulatingproteinandthecomplementcomponent3precursorareassociatedwiththeoccurrenceanddevelopmentofcoronaryheartdisease
AT guofang levelsofacylationstimulatingproteinandthecomplementcomponent3precursorareassociatedwiththeoccurrenceanddevelopmentofcoronaryheartdisease
AT xingzhaoqin levelsofacylationstimulatingproteinandthecomplementcomponent3precursorareassociatedwiththeoccurrenceanddevelopmentofcoronaryheartdisease
AT bupeili levelsofacylationstimulatingproteinandthecomplementcomponent3precursorareassociatedwiththeoccurrenceanddevelopmentofcoronaryheartdisease
AT liujidong levelsofacylationstimulatingproteinandthecomplementcomponent3precursorareassociatedwiththeoccurrenceanddevelopmentofcoronaryheartdisease